We investigated the effects of granulocyte-macrophage colony stimulating factor (GM-CSF) on behavioral and pathological outcomes in Alzheimer's disease (AD) and non-transgenic mice. GM-CSF treatment in AD mice reduced brain amyloidosis, increased plasma Aβ, and rescued cognitive impairment with increased hippocampal expression of calbindin and synaptophysin and increased levels of doublecortin-positive cells in the dentate gyrus. These data extend GM-CSF pleiotropic neuroprotection mechanisms in AD and include regulatory T cellmediated immunomodulation of microglial function, Aβ clearance, maintenance of synaptic integrity, and induction of neurogenesis. Together these data support further development of GM-CSF as a neuroprotective agent for AD.
Introduction
Innate and adaptive immunity are operative during progression of neurodegenerative disorders that include Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and stroke (Achim et al., 2009; Anderson et al., 2014; Olson and Gendelman, 2016) . These disorders show an inflammatory component linked to neural impairment or repair of the central nervous system (CNS). Immune competent microglia, macrophages, and dendritic cells produce factors that affect the brain's microenvironment with adaptive immunity, in part, also serving as a disease driver (Gendelman and Mosley, 2015; Huang et al., 2009 ). As such, misfolded proteins represented by α-synuclein neural inclusions in PD and amyloid-β (Aβ) accumulation in AD can alter immunologic tolerance and affect microglial activation leading to robust production of pro-inflammatory neurotoxins, oxidative stress, and excitotoxicity. All are linked to a spectrum of disorders beyond neurodegenerative disease that include nutritional deficiencies, drugs of abuse, neuroinfections, and depression (Calcia et al., 2016; DiSabato et al., 2016; Hurley and Tizabi, 2013; Maes et al., 2012; Mahgoub and Alexopoulos, 2016; Minihane et al., 2015) . On the one hand, disease-induced factors can be also harnessed for diagnostic and therapeutic gain in improving neural function. Hence research from our laboratory and others have aimed immune modulating strategies targeting immune-based activities to improve outcomes for neurodegenerative disorders (Kosloski et al., 2010; Olson and Gendelman, 2016; Puligujja et al., 2015) . Work is based on the notion that while effector T cells (Teffs) are neurodestructive and exacerbate immune activation and perpetuate neurodegenerative disease progression, regulatory T cells (Tregs) orchestrate self-tolerance, modulate microglial activation and support neuronal protection (Banerjee et al., 2008; Reynolds et al., 2007a; Reynolds et al., 2007b; Sakaguchi and Regulatory, 2000; Saresella et al., 2011; Takahashi et al., 2000) . Indeed, the balance between Treg-and Teffmediated immunomodulation is known to affect the tempo and progression of diseases. 
